Hannah Valantine Sells 2,808 Shares of BridgeBio Pharma (NASDAQ:BBIO) Stock

Posted by George Bondi on Jun 26th, 2026

BridgeBio Pharma, Inc. (NASDAQ:BBIO – Get Free Report) Director Hannah Valantine sold 2,808 shares of the company’s stock in a transaction on Monday, June 22nd. The shares were sold at an average price of $68.00, for a total value of $190,944.00. Following the completion of the sale, the director owned 11,455 shares of the company’s stock, valued at approximately $778,940. The trade was a 19.69% decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.

Hannah Valantine also recently made the following trade(s):

On Tuesday, June 23rd, Hannah Valantine sold 2,196 shares of BridgeBio Pharma stock. The stock was sold at an average price of $68.57, for a total value of $150,579.72.

BridgeBio Pharma Trading Up 0.5%

Shares of BBIO stock opened at $69.69 on Friday. BridgeBio Pharma, Inc. has a twelve month low of $41.80 and a twelve month high of $84.94. The company’s 50-day moving average price is $69.03 and its 200-day moving average price is $71.84. The stock has a market cap of $13.65 billion, a price-to-earnings ratio of -18.63 and a beta of 0.97.

BridgeBio Pharma (NASDAQ:BBIO – Get Free Report) last issued its earnings results on Thursday, May 7th. The company reported ($0.84) EPS for the quarter, missing analysts’ consensus estimates of ($0.70) by ($0.14). The business had revenue of $194.51 million for the quarter, compared to the consensus estimate of $178.07 million. BridgeBio Pharma’s revenue for the quarter was up 66.8% compared to the same quarter last year. During the same quarter in the previous year, the business earned ($0.88) earnings per share. As a group, equities research analysts predict that BridgeBio Pharma, Inc. will post -2.29 EPS for the current year.

Hedge Funds Weigh In On BridgeBio Pharma

Several large investors have recently made changes to their positions in BBIO. Janus Henderson Group PLC increased its holdings in BridgeBio Pharma by 19.8% in the 1st quarter. Janus Henderson Group PLC now owns 13,179,013 shares of the company’s stock valued at $978,608,000 after purchasing an additional 2,178,556 shares during the last quarter. Farallon Capital Management LLC lifted its stake in BridgeBio Pharma by 9.8% during the fourth quarter. Farallon Capital Management LLC now owns 8,998,463 shares of the company’s stock worth $688,292,000 after purchasing an additional 806,463 shares in the last quarter. Aisling Capital Management LP lifted its stake in BridgeBio Pharma by 0.4% during the third quarter. Aisling Capital Management LP now owns 6,089,611 shares of the company’s stock worth $316,294,000 after purchasing an additional 21,486 shares in the last quarter. Invesco Ltd. boosted its position in shares of BridgeBio Pharma by 23.0% during the fourth quarter. Invesco Ltd. now owns 4,831,305 shares of the company’s stock worth $369,547,000 after buying an additional 902,648 shares during the period. Finally, Geode Capital Management LLC grew its stake in shares of BridgeBio Pharma by 12.9% in the fourth quarter. Geode Capital Management LLC now owns 4,412,523 shares of the company’s stock valued at $344,689,000 after buying an additional 502,582 shares in the last quarter. 99.85% of the stock is currently owned by institutional investors and hedge funds.

Analyst Ratings Changes

Several analysts have recently commented on the stock. William Blair began coverage on shares of BridgeBio Pharma in a research report on Tuesday, March 10th. They set an “outperform” rating on the stock. Truist Financial raised their target price on BridgeBio Pharma from $95.00 to $102.00 and gave the stock a “buy” rating in a research note on Wednesday, April 29th. Leerink Partners restated an “outperform” rating and issued a $98.00 target price on shares of BridgeBio Pharma in a research report on Thursday, March 12th. Mizuho decreased their price target on BridgeBio Pharma from $106.00 to $96.00 and set an “outperform” rating on the stock in a research note on Tuesday, June 16th. Finally, Canaccord Genuity Group started coverage on BridgeBio Pharma in a report on Wednesday, June 3rd. They set a “buy” rating and a $104.00 price target for the company. Twenty-one equities research analysts have rated the stock with a Buy rating, two have issued a Hold rating and one has issued a Sell rating to the company. Based on data from MarketBeat, the stock has an average rating of “Moderate Buy” and an average target price of $92.90.

Check Out Our Latest Analysis on BBIO

About BridgeBio Pharma

(Get Free Report)

BridgeBio Pharma, Inc is a clinical-stage biopharmaceutical company headquartered in Palo Alto, California. Founded in 2015 by Neil Kumar, the company is dedicated to discovering, developing and delivering transformative medicines for patients with genetic diseases and cancers. BridgeBio operates an integrated model that spans target identification, preclinical research, clinical development and commercialization, aiming to streamline the process from bench to bedside.

BridgeBio’s pipeline comprises multiple therapeutic modalities, including small molecules, biologics and genetic therapies.